Cardiac Arrest in a Toddler Treated with Propranolol for Infantile Hemangioma: a Case Report

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2017 Nov 19

PMID 29149854

Citations 2

Authors

Alvise Tosoni

Mario Cutrone

Maurizio Dalle Carbonare

Andrea Pettenazzo

Giorgio Perilongo

Stefano Sartori

Affiliations

Soon will be listed here.

Abstract

Background: Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile.

Case Presentation: We report the case of a toddler, on propranolol, who suffered cardiac arrest during an acute viral infection. She had a neurally-mediated syncope that progressed to asystole, probably because of concurrent factors as dehydration, beta-blocking and probably individual susceptibility to vaso-vagal phenomena. In fact a significant history of breath-holding spells was consistent with vagal hyperactivity.

Conclusions: The number of patients treated with propranolol for IHs will increase and sharing experience will help to better define the safety profile of this drug.

Citing Articles

Cardiac Evaluation before and after Oral Propranolol Treatment for Infantile Hemangiomas.

Kwak J, Yang A, Jung H, Kim H, Kim D, Shim J J Clin Med. 2024; 13(11).

PMID: 38893043 PMC: 11172932. DOI: 10.3390/jcm13113332.

Deep coma in a child treated with propranolol for infantile hemangioma.

Bakalli I, Kola E, Lluka R, Celaj E, Sala D, Gjeta I BMC Pediatr. 2019; 19(1):216.

PMID: 31266444 PMC: 6604368. DOI: 10.1186/s12887-019-1598-0.

References

Sowinski K, Burlew B . Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy. 1997; 17(6):1305-10. View

El Hachem M, Gesualdo F, Diociaiuti A, Berti I, Vercellino N, Boccaletti V . Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. Ital J Pediatr. 2017; 43(1):40. PMC: 5395924. DOI: 10.1186/s13052-017-0357-9. View

Zvulunov A, McCuaig C, Frieden I, Mancini A, Puttgen K, Dohil M . Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011; 28(2):94-8. DOI: 10.1111/j.1525-1470.2010.01379.x. View

Pratico A, Caraci F, Pavone P, Falsaperla R, Drago F, Ruggieri M . Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas. Drug Saf Case Rep. 2016; 2(1):6. PMC: 5005742. DOI: 10.1007/s40800-015-0009-1. View

Sartori S, Nosadini M, Leoni L, De Palma L, Toldo I, Milanesi O . Pacemaker in complicated and refractory breath-holding spells: when to think about it?. Brain Dev. 2014; 37(1):2-12. DOI: 10.1016/j.braindev.2014.02.004. View

Vivas-Colmenares G, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas J, Fernandez-Pineda I . Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol. 2015; 32(3):348-52. DOI: 10.1111/pde.12520. View

Darrow D, Greene A, Mancini A, Nopper A . Diagnosis and Management of Infantile Hemangioma. Pediatrics. 2015; 136(4):e1060-104. DOI: 10.1542/peds.2015-2485. View

Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G . A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015; 372(8):735-46. DOI: 10.1056/NEJMoa1404710. View

Ward S, Walle T, Walle U, Wilkinson G, Branch R . Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989; 45(1):72-9. DOI: 10.1038/clpt.1989.11. View

10.

Albuquerque J, Magalhaes R, Felix J, Bastos M, Fontenele J, Trompieri N . Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. Sao Paulo Med J. 2014; 132(1):48-54. PMC: 10889460. DOI: 10.1590/1516-3180.2014.1321575. View

11.

Kelly A, Porter C, McGoon M, Espinosa R, Osborn M, Hayes D . Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics. 2001; 108(3):698-702. DOI: 10.1542/peds.108.3.698. View

12.

Wang D, Poi M, Sun X, Gaedigk A, Leeder J, Sadee W . Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2013; 23(1):268-78. PMC: 3857955. DOI: 10.1093/hmg/ddt417. View

13.

Legge L, Kantoch M, Seshia S, Soni R . A pacemaker for asystole in breath-holding spells. Paediatr Child Health. 2010; 7(4):251-4. PMC: 2794823. DOI: 10.1093/pch/7.4.251. View

14.

Leaute-Labreze C, Harper J, Hoeger P . Infantile haemangioma. Lancet. 2017; 390(10089):85-94. DOI: 10.1016/S0140-6736(16)00645-0. View

15.

Saidi W, Zaouali A, Saihi N, Mokni S, Denguezli M, Nouira R . [Cardiorespiratory arrest following bronchiolitis in a child treated with propranolol for hemangioma]. Ann Dermatol Venereol. 2014; 141(8-9):528-9. DOI: 10.1016/j.annder.2014.04.111. View

16.

Prey S, Voisard J, Delarue A, Lebbe G, Taieb A, Leaute-Labreze C . Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA. 2016; 315(4):413-5. DOI: 10.1001/jama.2015.13969. View

17.

Hoeger P, Harper J, Baselga E, Bonnet D, Boon L, Ciofi Degli Atti M . Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015; 174(7):855-65. DOI: 10.1007/s00431-015-2570-0. View